Factors affecting adherence and convenience in antiretroviral therapy

Palella FJ , Delaney KM , Moorman AC Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;388:853

Haynes RB . Determinants of compliance: the disease and the mechanics of treatment. In: Haynes RB , Sackett DL , eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press, 1979; 4962

Gir E , Bunch EH , Holzerner WL . Adherence to anti-retroviral therapy: a four-country comparison. 12th International AIDS Conference. Geneva, Switzerland, June-July 1998. Abstract 60129

Eldred LJ , Wu AW , Chaisson RE , Moore RD . Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:11725

Paterson DL , Swindells S , Mohr JA Adherence with protease inhibitor therapy for human immunodeficiency virus infection. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA, September 1998. Abstract I-172

Chesney MA , Ickovics JR , Chambers DB Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000;12:25566

Gallant JE , Block DS . Adherence to antiretroviral regimens in HIV-infected patients: results of a survey among physicians and patients. J Int Assoc Physicians AID Care (JIAPAC) May 1998 [(http://iapac.org/dinmgt/avfherapies/gallant_survey.html)]

Bartlett JA . Correlation between antiretroviral pill burden and durability of virologie response — a systematic overview. 13th International AIDS Conference. Durban, South Africa, July 2000. Abstract ThPeB4998

Molina JM , Ferchal F , Rancinan C A pilot study of FTC+ ddI + efavirenz in treatment-naïve HIV-infected adults: a potent and convenient once-a-day HAART (ANRS 091 trial). 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, January-February 2000. Abstract 518

Luskin-Hawk R , Cohen C , Lang J Efavirenz is well tolerated and highly efficacious in combination with the nucleosides stavudine (d4T) + didanosine (ddI) or d4T + lamivudine (3TC). 37th Annual Meeting of the Infectious Disease Society of America. Philadelphia, USA, November 1999. Abstract 349

Suleiman J , Rhodes R , Campo R Preliminary results from indinavir (IDV) and ritonavir (RTV) in a once-daily regimen (Marck 103/104). 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 2001. Abstract 336

Saag MS , Kilby M , Ehrensing E Saquinavir systemic exposure and safety of once-daily administration of Fortovase™ (saquinavir) soft gel capsule (FTV) in combination with low-dose ritonavir (RTV). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA, September 1999. Abstract 330

Squires K , Gatell J , Piliero P , Sannel I , Wood R , Schnittman SM . A1424-007: 48-week safety and efficacy results from a Phase II study of a once-daily HIV-1 protease inhibitor (PI), BMS-232632. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 2001. Abstract 15

Van Heeswijk RP , Veldkamp AI , Mulder JW The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000;14:F7782

Hsu A . Modelling effect of pharmacokinetics/adherence on protease inhibitors (PI) qd and bid regimens. 13th International AIDS Conference. Durban, South Africa, July 2000. Abstract TuPeB3302

Tashima K , Staszewski S , Morales-Ramirez JO Efavirenz (EFV) + ZDV + 3TC provides superior long-term HIV-RNA suppression, antiretroviral activity and tolerability versus IDV + ZDV + 3TC: results of Study 006 at 72 weeks (initial cohort). 37th Annual Meeting of the Infectious Disease Society of America. Philadelphia, USA, November 1999. Abstract 366

Arribas J , Staszewski S , Nelson M Three-year durability of response with an efavirenz (EFV)-containing regimen: 144-week follow-up from Study 006. 11th European Congress of Clinical Microbiology and Infectious Diseases. Istanbul, Turkey, April 2001. Abstract 043

Cohen C , Elion R , Green S SUSTIVA™ (efavirenz) is highly effective and well tolerated in combination with the nucleosides stavudine and lamivudine (Study DMP 266-043). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 2000. Abstract 538

Riddler S , Kahn J , Martin G Durable HIV suppression and tolerability with efavirenz (EFV) + indinavir (IDV): results at 132 weeks (Study 003-Cohort IV). 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, January-February 2000. Abstract 513

Montaner JSG , Reiss P , Cooper D Long-term follow-up of patients treated with nevirapine (NVP) based combination therapy within the INCAS trial. 12th International AIDS Conference. Geneva, Switzerland, June-July 1998. Abstract 12368

Montaner JSG , Reiss P , Cooper D A randomized, double-blind trial comparing combination of nevirapine, didanosine and zidovudine for HIV-infected patients. The INCAS trial. JAMA 1998;279:9307

Molina JM , Ferchal F , Ran ein an C Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000;182 (2):599602

Molina JM , Perusat S , Ferchal F Once-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment-naïve, HIV-infected adults: 64-week follow-up of the ANRS 091 trial. 8th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, January-February 2001. Abstract 321

Maggiolo F , Migliorino M , Rizzi M Once-a-day therapy for HIV infection. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 2000. Abstract 1520

Maggiolo F , Migliorino M , Maserati R Once-a-day treatment for HIV infection: final 48-week results. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 2001. Abstract 320

Landman R , Schiemann R , Thiam S First evaluation of a once-a-day HAART regimen in treatment-naïve HIV-1 infected adults in Senegal. ANRS 12-04/IMEA 011 study. 13th International AIDS Conference. Durban, South Africa, July 2000. Abstract LbPp102

Proença P , Sá J , Xavier A Once-daily therapy with nevirapine (Nev)/didanosine (ddI)/lamivudine (3TC) in a non-adherent population. 13th International AIDS Conference. Durban, South Africa, July 2000. Abstract TuPeB3231

Veldkemp AI , Hoetelmans RMW , Beijnen JH The pharmacokinetics (PK) of once daily nevirapine (NVP) and efavirenz (EFV) when used in combination. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, January-February 2001. Abstract 80

Jordan WC , Jefferson R , Yemofio F Nevirapine (NVP) + efavirenz (LFV) +didanosine (ddI): a simple, safe, and effective once-daily regimen. 13th International AIDS Conference. Durban, South Africa, July 2000. Abstract TuPeB3207

Max B , Sherer R . Management of the adverse effects of antiretroviral therapy, and medication adherence. Clin Infect Dis 2000;30: S96116

Bartlett JA . Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 2001. Abstract 19

Goldenberg D , Boyle B , Vaamonde C Psychiatric illness and efavirenz study (PIES). 13th International AIDS Conference. Durban, South Africa, July 2000. Abstract WePeb4238

Knobel H , Miro JM , De-Miguel V Efficacy of a short-term prednisolone regimen in nevirapine associated rash prevention: a double-blind placebo-controlled clinical trial. Results of the GESIDA 09/99 study. 13th International AIDS Conference. Durban, South Africa, July 2000. Abstract L-15